Citigroup’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-110
| Closed | -$1.81K | – | 5946 |
|
|
2023
Q4 | $1.81K | Hold |
110
| – | – | ﹤0.01% | 5434 |
|
|
2023
Q3 | $854 | Hold |
110
| – | – | ﹤0.01% | 5115 |
|
|
2023
Q2 | $571 | Sell |
110
-167,622
| -100% | -$854K | ﹤0.01% | 5368 |
|
|
2023
Q1 | $901K | Buy |
167,732
+167,622
| +152,384% | +$912K | ﹤0.01% | 2641 |
|
|
2022
Q4 | $408 | Sell |
110
-8
| -7% | -$35 | ﹤0.01% | 5531 |
|
|
2022
Q3 | $1K | Sell |
118
-4,955
| -98% | -$27.6K | ﹤0.01% | 5723 |
|
|
2022
Q2 | $30K | Buy |
5,073
+3,151
| +164% | +$17.8K | ﹤0.01% | 4794 |
|
|
2022
Q1 | $14K | Buy |
1,922
+1,806
| +1,557% | +$17.7K | ﹤0.01% | 5374 |
|
|
2021
Q4 | $2K | Sell |
116
-14,160
| -99% | -$234K | ﹤0.01% | 5741 |
|
|
2021
Q3 | $328K | Buy |
14,276
+2,428
| +20% | +$72.2K | ﹤0.01% | 3884 |
|
|
2021
Q2 | $520K | Buy |
11,848
+8,308
| +235% | +$463K | ﹤0.01% | 3677 |
|
|
2021
Q1 | $257K | Buy |
3,540
+1,512
| +75% | +$107K | ﹤0.01% | 3874 |
|
|
2020
Q4 | $88K | Buy |
2,028
+1,445
| +248% | +$64.7K | ﹤0.01% | 5633 |
|
|
2020
Q3 | $24K | Buy |
583
+54
| +10% | +$2.79K | ﹤0.01% | 6070 |
|
|
2020
Q2 | $32K | Sell |
529
-764
| -59% | -$70K | ﹤0.01% | 6282 |
|
|
2020
Q1 | $97K | Buy |
1,293
+991
| +328% | +$114K | ﹤0.01% | 5368 |
|
|
2019
Q4 | $42K | Buy |
+302
| New | +$36.7K | ﹤0.01% | 6455 |
|
Citigroup's ORTX Position: Q1 2024 in Review
Citigroup sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q1 2024, closing a stake of 110 shares — an estimated $1.81K sold.
Citigroup first reported a position in ORTX in Q4 2019 and held it in 17 quarters. The position peaked at $901K in Q1 2023. 0 funds tracked by Wall St. Rank hold ORTX as of Q1 2024.
- Citigroup reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q1 2024 after selling out during the quarter.
- Citigroup sold 110 Orchard Therapeutics plc American Depositary Shares shares in Q1 2024, an estimated $1.81K.
- Citigroup first reported a position in Orchard Therapeutics plc American Depositary Shares in Q4 2019 and held it in 17 quarters.
- Citigroup's Orchard Therapeutics plc American Depositary Shares position peaked at $901K in Q1 2023.
- 0 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q1 2024.
Based on Citigroup's 13F filing for Q1 2024, filed 10 May 2024.